Ligand Invests $75 Mln Royalty Financing In Castle Creek Biosciences
25/2 18:48
(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Tuesday announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullo...